CTOs on the Move

Innocrin Pharmaceuticals

www.innocrinpharma.com

 
Innocrin discovers and develops novel, best-in-class oral inhibitors of CYP17 lyase, a validated enzyme target for the treatment of castration-resistant prostate cancer (CRPC). VT-464 and structurally-related classes of CYP17 inhibitors are wholly owned by Innocrin. CYP17 lyase inhibitors may also have high commercial potential for the treatment of breast cancer as well as non-oncologic syndromes that are due to hormonal excess including endometriosis, polycystic ovary syndrome and congenital adrenal hyperplasia.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

CNS Healthcare

Providing mental health and substance use disorder services for children, youth, and adults. No insurance needed. #EndStigma

Porzio Life Sciences

Regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations.

Sisters of Saint Joseph of Philadelphia

We are a community of approximately 825 women religious. Originally founded in 1650 in LePuy, France, the Sisters of Saint Joseph came to Philadelphia in 1847. Through our many ministries, including educations, healthcare, social services and parish m...

Ipsen

Ipsen S.A. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Pharmasset

Pharmasset, Inc. is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.